Federal judge lifts temporary restraining order against DEA; action now moves to DEA administrative judge
The surprise suspension of Cardinal Health's Lakeland, FL distribution center to handle controlled substances is back in force. When the DEA action occurred on Feb. 3, Cardinal immediately moved for, and won, a temporary restraining order in federal court; in Cardinal Health Inc. v Holder, US District Court, District of Columbia, No. 12-185, Judge Reggie Walton has now agreed with DEA that the suspension is valid. The next step is an administrative law hearing within DEA, scheduled for Apr. 3; Cardinal, meanwhile, plans to appeal the federal ruling.
Fitch Ratings, a corporate-credit rating service, says that the suspension will have little effect on Cardinal's finances; the controlled substances distribution from Lakeland represents about 2% of the company's pharmaceutical volume. Cardinal has stated that it plans to fill Lakeland controlled-substances orders from DCs in Mississippi and North Carolina.
"We have genuine respect for the work of the DEA, but effectively addressing prescription drug abuse requires a very different approach than does the war on illicit drugs," Cardinal said in a statement issued after the ruling. "We want to work collaboratively with all participants in the drug supply chain — including regulators, pharmaceutical manufacturers, distributors, pharmacists, doctors and boards of pharmacy – to combat this serious nationwide issue. We want to be part of a new, more effective solution to stop prescription drug abuse, without disrupting legitimate use."
In other documents, Cardinal has pointed out that DEA receives data from pharmacies like those blamed for the high volume of controlled substances that were the cause of the suspension, and that DEA itself has noted that a decision on the legitimacy of drug orders from a pharmacy cannot be based solely on spikes in volume. (DEA has contended that over three million doses had been ordered by the pharmacies, while a "average" order volume would be around 69,000 annually.) In instituting the suspension, DEA claims that there is an "imminent danger to public safety," and, essentially, Judge Walton agreed.
Press reports indicate that the process of reviewing the suspension and possibly re-instituting Cardinal's license could take as long as a year.
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
Reimagining Closed-Loop Marketing Strategies for Pharma Companies
November 21st 2024The pharmaceutical industry is evolving, and so are the strategies needed to connect with healthcare professionals. Closed-loop marketing (CLM) has become essential in delivering personalized, data-driven engagement that resonates with physicians and improves key outcomes, such as enhancing patient care, increasing
Maximize Pharma’s Potential with AI-Ready Data for Commercial Excellence
November 21st 2024As the pharmaceutical industry embraces the power of AI, having data that’s large, diverse, and well-structured is critical for driving innovation and improving outcomes. Ensuring your data is AI-ready and can be used with more advanced solutions enables your teams to make informed strategic decisions, predict trends, enhance customer engagements and drive overall strategy.